Autoimmune Association Endorses Safe Step Act of 2021 with Safe Step Act Coalition
AARDA endorsed the Safe Step Act of 2021, bill that would amend the Employee Retirement Income Security Act (ERISA) to require a group health plan provide an exception process for any medication step therapy protocol. Autoimmune Association joined the Safe Step Act Coalition in this sign-on letter.
Autoimmune Association Sends Letter of Support to Nebraska Legislature on Legislation To Protect Patients By Requiring Step Therapy Policies Be Based on Medical Reasons
AARDA sent a letter of support to the Nebraska Legislature on January 29 for LB 337, a bill that would provide patient protections by requiring step therapy policies in the state to be based on current evidence and for medical reasons only.
Autoimmune Association Issues Statement on HHS Decision to Delay Implementation of Rebate Rule
AARDA issued a statement on January 29 urging the Biden Administration to act promptly and without further delay on the HHS rule implementing the final rebate rule that would direct PBM savings to patients. “Many don’t have the luxury of waiting to get access to the treatments they rely upon. Delaying implementation would have significant negative implications on patients.”
Autoimmune Association Signs On to ACS CAN-Partners Letter to HHS Regarding CMMI Part D Payment Modernization Models and the Six Protected Classes Flexibilities
AARDA signed on to a letter on January 28 submitted by ACS CAN Partners commenting on the six protected classes flexibilities in the Centers for Medicaid & Medicaid Innovation (CMMI) Part D Payment Modernization Model for 2022. The two new options allow for Part D plan sponsors to limit drug coverage to at least one drug per class, potentially jeopardizing beneficiary access to medically necessary prescription drugs and harming patients with serious illness.
Autoimmune Association Signs Letter Voicing Concerns on Washington Price Controls Bill Incorporating ICER Value Assessment
AARDA signed on to a letter on January 26 voicing concerns regarding SB 5020, a bill that proposed lowering costs by allowing ICER to make value judgements about patients’ quality of life. Autoimmune Association has been vocal regarding ICER’s use of QALY measurements in their value assessments due to these practices being discriminatory against older individuals or those with chronic diseases and disabilities.
Autoimmune Association Sends Letter to UnitedHealthcare Regarding Remicade Coverage
AARDA sent a letter on January 25 to UnitedHealthcare regarding a mid-year change in coverage for Remicade. Abruptly changing Remicade from a preferred to non-preferred medicine in coverage mid-year could be disruptive to stable patients and their care. This action by the plan, and not the patient’s prescriber, is an example of a nonmedical switch. AARDA’s objection to this action is independent of the medication, and believes it to be inconsistent with the principles laid out by Let My Doctors Decide, a campaign endorsed by Autoimmune Association and many other organizations representing patient groups.
Autoimmune Association Submits Letter to CMS on Most Favored Nation Model Interim Final Rule
AARDA submitted a letter on January 26 commenting on the Most Favored Nation (MFN) Interim Final Rule with Comment Period (IFC) issued by the Centers for Medicare and Medicaid Services (CMS). Autoimmune Association expressed graves concerns regarding the IFC from both a legal and public policy perspective and urged the agency to rescind the IFC. For millions of patients who rely on prescription medications covered under Medicare Part B, this “model” under the IFC, could restrict patients’ access to treatments that manage their conditions, forcing them to either forego therapy or to seek treatments in more expensive and potentially less safe provider settings. This issue, along with procedural, legal, ethical, and other substantive policy concerns force Autoimmune Association to request the IFC to be withdrawn.